Dr Emily Richardson is a Lead Scientist in the R&D team at CN Bio. She joined the team in 2020 as a Senior Scientist and lead the development of the PhysioMimix® lung and lung-liver MPS models. Emily is highly experienced in the application of complex cell biology to drug discovery, having previously worked in cellular therapeutics in an industry setting and as a trained biochemist with specialty in molecular biology. She completed her PhD at the University of Leicester, using 3D cell culture to determine molecular mechanisms driving highly metastatic lung cancers. She now leads R&D projects within the CN Bio team revolving around toxicology in the liver and the lung MPS, as well as driving collaborative projects with various academic, industry and regulatory partners.

Isavella is a Research Assistant in the Toxicology R&D team at CN Bio. She holds an MRes in Regenerative Medicine and Stem Cell Biology, as well as a BSc in Biochemistry from Newcastle University. With a strong background in in vitro toxicology, Isavella has played a key role in CN Bio’s safety toxicology initiatives, with contributions in developing the rat (Sprague-Dawley) and dog (Beagle) Liver MPS models for cross-species DILI analysis, as well as the DILI assay kit:Human 24.